Project 3

项目3

基本信息

  • 批准号:
    6359886
  • 负责人:
  • 金额:
    $ 35.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-30 至 2005-05-31
  • 项目状态:
    已结题

项目摘要

Individual's infected with the human immunodeficiency virus (HIV-1) frequently exhibit serious, progressive behavioral, cognitive and motor deficits (termed NeuroAIDS) in association with pathological changes (including gliosis, encephalitis and vacuolar myelopathy) in the brain. Current evidence strongly indicate the pathogenesis of this disorder (also known as NeuroAIDS) involves neurotoxic pathways mediated by: (1) HIV-1 related products e.g. the envelope protein gp120 and (2) products of the host response exemplified by cytokines such as IL-6, IFN- and TNF, release from activated macrophage/microglia and astroglia. Methamphetamine (METH) abuse which is frequently accomplished by significant acute and long-term neuronal damage is prevalent amongst HIV-1 infected individuals. We hypothesize here that the combination of these viral, host and METH insults produce additive or even synergistic actions that result in the worsening of the neuropathological sequelae and an accelerated progression to the functional neuropsychiatric deficits of NeuroAIDS. To determine the nature and mechanisms by which the central stimulant drug METH interacts with host-derived and HIV-1 related products to influence the degree and progression of structural and functional central nervous system (CNS) injury. Dysregulated peripheral immune function resulting from HIV-1 infection as well as infection from additional infectious agents is observed in individuals with AIDS. Therefore, we will define the interactions between METH and peripheral immune stimulation (achieved by intraperitoneal injection of the potent immune stimulant lipopolysaccharide) to influence the severity and progression of both CNS host responses and neuropathology. Transgenic mice with cerebral expression of IL6, TNF-, TNF- or gp120 recapitulate many of the structural and functional features of NeuroAIDS and will be used in the proposed studies to elucidate the interactions between METH and the central production of host- or HIV-1- related products to the development and progression of CNS host responses and neuropathology. Finally, transgenic mice with over-expression of Cu/Zn superoxide dismutase (SOD) or deficient expression of tissue-type plasminogen activator (tPA) that may underlie the pathogenic interactions between METH and products of the host response or HIV-1. This research plan integrates analysis of drug effects on the CNS as it relates to components of HIV disease progression is an important question for pre clinical and clinical research, as substance abusers have a high risk for exposure to the virus. The proposed studies should go far in identifying critical viral- and host-derived factors associated with increased susceptibility to the pathological effects of drugs of abuse such as METH and consequent neurotoxicity.
感染人类免疫缺陷病毒(HIV-1)的个体经常表现出与脑中的病理变化(包括神经胶质增生、脑炎和空泡性脊髓病)相关的严重的、进行性的行为、认知和运动缺陷(称为NeuroAIDS)。目前的证据强烈表明这种疾病(也称为NeuroAIDS)的发病机制涉及由以下介导的神经毒性途径:(1)HIV-1相关产物,例如包膜蛋白gp 120和(2)宿主应答的产物,例如从活化的巨噬细胞/小胶质细胞和星形胶质细胞释放的细胞因子,如IL-6、IFN-γ和TNF。甲基苯丙胺(METH)滥用是HIV-1感染者中普遍存在的一种滥用,通常是通过严重的急性和长期的神经元损伤来实现的。我们在此假设,这些病毒、宿主和METH损伤的组合产生相加或甚至协同作用,导致神经病理学后遗症的恶化和加速进展为NeuroAIDS的功能性神经精神缺陷。确定中枢兴奋剂药物METH与宿主衍生和HIV-1相关产物相互作用的性质和机制,以影响结构和功能性中枢神经系统(CNS)损伤的程度和进展。在艾滋病患者中观察到由HIV-1感染以及其他感染因子感染引起的外周免疫功能失调。因此,我们将确定METH和外周免疫刺激(通过腹腔注射强效免疫刺激剂脂多糖实现)之间的相互作用,以影响CNS宿主反应和神经病理学的严重程度和进展。脑表达IL 6,TNF-,TNF-或gp 120的转基因小鼠概括了NeuroAIDS的许多结构和功能特征,并将用于拟议的研究,以阐明METH和中枢产生的宿主或HIV-1相关产物之间的相互作用,以发展和CNS宿主反应和神经病理学的进展。最后,铜/锌超氧化物歧化酶(SOD)过度表达或组织型纤溶酶原激活物(tPA)表达不足的转基因小鼠,可能是METH和宿主反应或HIV-1产物之间的致病性相互作用的基础。该研究计划整合了药物对中枢神经系统影响的分析,因为它与艾滋病毒疾病进展的组成部分相关,这是临床前和临床研究的一个重要问题,因为药物滥用者接触病毒的风险很高。拟议的研究应在确定关键的病毒和宿主衍生的因素与增加的易感性滥用药物的病理影响,如甲基和随之而来的神经毒性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IAIN Leslie CAMPBELL其他文献

IAIN Leslie CAMPBELL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IAIN Leslie CAMPBELL', 18)}}的其他基金

CNS Pathobiology of IFN-inducible non-ELR CXC Chemokines
IFN 诱导的非 ELR CXC 趋化因子的 CNS 病理学
  • 批准号:
    6911638
  • 财政年份:
    2004
  • 资助金额:
    $ 35.07万
  • 项目类别:
CNS Pathobiology of IFN-inducible non-ELR CXC Chemokines
IFN 诱导的非 ELR CXC 趋化因子的 CNS 病理学
  • 批准号:
    7234038
  • 财政年份:
    2004
  • 资助金额:
    $ 35.07万
  • 项目类别:
CNS Pathobiology of IFN-inducible non-ELR CXC Chemokines
IFN 诱导的非 ELR CXC 趋化因子的 CNS 病理学
  • 批准号:
    7432448
  • 财政年份:
    2004
  • 资助金额:
    $ 35.07万
  • 项目类别:
CNS Pathobiology of IFN-inducible non-ELR CXC Chemokines
IFN 诱导的非 ELR CXC 趋化因子的 CNS 病理学
  • 批准号:
    7056082
  • 财政年份:
    2004
  • 资助金额:
    $ 35.07万
  • 项目类别:
CNS Pathobiology of IFN-inducible non-ELR CXC Chemokines
IFN 诱导的非 ELR CXC 趋化因子的 CNS 病理学
  • 批准号:
    6704589
  • 财政年份:
    2004
  • 资助金额:
    $ 35.07万
  • 项目类别:
Project 3
项目3
  • 批准号:
    6594213
  • 财政年份:
    2002
  • 资助金额:
    $ 35.07万
  • 项目类别:
Project 3
项目3
  • 批准号:
    6663386
  • 财政年份:
    2002
  • 资助金额:
    $ 35.07万
  • 项目类别:
Project 3
项目3
  • 批准号:
    6464633
  • 财政年份:
    2001
  • 资助金额:
    $ 35.07万
  • 项目类别:
IFN-ALPHA AND HIV GP120 IN NEUROAIDS STUDIES
神经艾滋病研究中的 IFN-α 和 HIV GP120
  • 批准号:
    6539175
  • 财政年份:
    2000
  • 资助金额:
    $ 35.07万
  • 项目类别:
IFN-ALPHA AND HIV GP120 IN NEUROAIDS STUDIES
IFN-α 和 HIV GP120 在神经艾滋病研究中的应用
  • 批准号:
    6751992
  • 财政年份:
    2000
  • 资助金额:
    $ 35.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了